ADMA Biologics, Inc. (NASDAQ: ADMA) Stock Competitors & Peer Comparison
See ADMA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ADMA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADMA | $8.27 | -1.19% | 1.9B | 11.81 | $0.70 | N/A |
| VRTX | $477.36 | +0.90% | 121.1B | 25.36 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $656.01 | +0.63% | 67.6B | 14.38 | $45.63 | +0.55% |
| ARGX | $918.22 | -0.69% | 57.1B | 82.87 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.50 | -0.31% | 41.8B | -2.29 | -$4.15 | N/A |
| RVMD | $189.23 | +0.25% | 40.2B | -26.77 | -$7.07 | N/A |
| ALNY | $271.77 | +1.13% | 36.3B | 48.97 | $5.55 | N/A |
| ONC | $325.90 | -0.27% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ADMA vs VRTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while VRTX trades at $477.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas VRTX's P/E ratio is 25.36. In terms of profitability, ADMA's ROE is +0.39%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ADMA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
ADMA vs VRNA Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ADMA's ROE is +0.39%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ADMA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ADMA vs REGN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while REGN trades at $656.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas REGN's P/E ratio is 14.38. In terms of profitability, ADMA's ROE is +0.39%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ADMA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
ADMA vs ARGX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ARGX has a market cap of 57.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ARGX trades at $918.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ARGX's P/E ratio is 82.87. In terms of profitability, ADMA's ROE is +0.39%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, ADMA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ADMA vs SGEN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ADMA's ROE is +0.39%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ADMA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ADMA vs RVMDW Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while RVMDW trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas RVMDW's P/E ratio is -2.29. In terms of profitability, ADMA's ROE is +0.39%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ADMA is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ADMA vs RVMD Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, RVMD has a market cap of 40.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while RVMD trades at $189.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas RVMD's P/E ratio is -26.77. In terms of profitability, ADMA's ROE is +0.39%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ADMA is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check RVMD's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ADMA vs ALNY Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ALNY has a market cap of 36.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ALNY trades at $271.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ALNY's P/E ratio is 48.97. In terms of profitability, ADMA's ROE is +0.39%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ADMA is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
ADMA vs ONC Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ONC's P/E ratio is 72.91. In terms of profitability, ADMA's ROE is +0.39%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ADMA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ADMA vs ROIV Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ROIV trades at $35.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ROIV's P/E ratio is -35.99. In terms of profitability, ADMA's ROE is +0.39%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ADMA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
ADMA vs INCY Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while INCY trades at $117.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas INCY's P/E ratio is 15.82. In terms of profitability, ADMA's ROE is +0.39%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ADMA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check INCY's competition here
Insmed Incorporated (NASDAQ: INSM)
ADMA vs INSM Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while INSM trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas INSM's P/E ratio is -18.59. In terms of profitability, ADMA's ROE is +0.39%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ADMA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
ADMA vs BNTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while BNTX trades at $89.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas BNTX's P/E ratio is -19.34. In terms of profitability, ADMA's ROE is +0.39%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ADMA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ADMA vs UTHR Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while UTHR trades at $528.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas UTHR's P/E ratio is 19.51. In terms of profitability, ADMA's ROE is +0.39%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ADMA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
ADMA vs MRNA Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while MRNA trades at $54.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas MRNA's P/E ratio is -6.63. In terms of profitability, ADMA's ROE is +0.39%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ADMA is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ADMA vs BGNE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ADMA's ROE is +0.39%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ADMA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ADMA vs DNA-WT Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ADMA's ROE is +0.39%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ADMA is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
ADMA vs GMAB Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas GMAB's P/E ratio is 20.77. In terms of profitability, ADMA's ROE is +0.39%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ADMA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ADMA vs NBIX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while NBIX trades at $175.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas NBIX's P/E ratio is 25.40. In terms of profitability, ADMA's ROE is +0.39%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ADMA is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check NBIX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ADMA vs BBIO Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while BBIO trades at $84.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas BBIO's P/E ratio is -22.47. In terms of profitability, ADMA's ROE is +0.39%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ADMA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ADMA vs JAZZ Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while JAZZ trades at $253.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas JAZZ's P/E ratio is 19.74. In terms of profitability, ADMA's ROE is +0.39%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ADMA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ADMA vs ASND Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ASND trades at $253.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ASND's P/E ratio is -104.90. In terms of profitability, ADMA's ROE is +0.39%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ADMA is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ADMA vs EXEL Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, EXEL has a market cap of 13.9B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while EXEL trades at $55.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas EXEL's P/E ratio is 16.58. In terms of profitability, ADMA's ROE is +0.39%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ADMA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ADMA vs KRTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ADMA's ROE is +0.39%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ADMA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ADMA vs MDGL Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while MDGL trades at $544.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas MDGL's P/E ratio is -42.54. In terms of profitability, ADMA's ROE is +0.39%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ADMA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check MDGL's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ADMA vs AXSM Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while AXSM trades at $241.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas AXSM's P/E ratio is -62.92. In terms of profitability, ADMA's ROE is +0.39%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ADMA is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ADMA vs ARWR Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ARWR has a market cap of 12.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ARWR trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ARWR's P/E ratio is -39.81. In terms of profitability, ADMA's ROE is +0.39%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ADMA is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ADMA vs BMRN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while BMRN trades at $59.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas BMRN's P/E ratio is 28.52. In terms of profitability, ADMA's ROE is +0.39%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ADMA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ADMA vs RNAM Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ADMA's ROE is +0.39%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ADMA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ADMA vs TECH Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while TECH trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas TECH's P/E ratio is 36.91. In terms of profitability, ADMA's ROE is +0.39%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ADMA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check TECH's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ADMA vs SMMT Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while SMMT trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas SMMT's P/E ratio is -8.54. In terms of profitability, ADMA's ROE is +0.39%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ADMA is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ADMA vs CYTK Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CYTK trades at $80.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CYTK's P/E ratio is -13.85. In terms of profitability, ADMA's ROE is +0.39%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ADMA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CYTK's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ADMA vs KRYS Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while KRYS trades at $335.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas KRYS's P/E ratio is 44.81. In terms of profitability, ADMA's ROE is +0.39%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ADMA is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ADMA vs HALO Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while HALO trades at $81.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas HALO's P/E ratio is 17.73. In terms of profitability, ADMA's ROE is +0.39%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ADMA is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ADMA vs RXDX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ADMA's ROE is +0.39%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ADMA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check RXDX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ADMA vs IONS Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, IONS has a market cap of 9.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while IONS trades at $56.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas IONS's P/E ratio is -32.88. In terms of profitability, ADMA's ROE is +0.39%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ADMA is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check IONS's competition here
Abivax S.A. (NASDAQ: ABVX)
ADMA vs ABVX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ABVX trades at $125.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ABVX's P/E ratio is -65.89. In terms of profitability, ADMA's ROE is +0.39%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ADMA is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ADMA vs NUVL Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ADMA's ROE is +0.39%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ADMA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ADMA vs KYMR Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while KYMR trades at $110.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas KYMR's P/E ratio is -31.32. In terms of profitability, ADMA's ROE is +0.39%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ADMA is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ADMA vs CRNX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CRNX trades at $83.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CRNX's P/E ratio is -16.32. In terms of profitability, ADMA's ROE is +0.39%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ADMA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CRNX's competition here
Alkermes plc (NASDAQ: ALKS)
ADMA vs ALKS Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ALKS trades at $52.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ALKS's P/E ratio is 55.67. In terms of profitability, ADMA's ROE is +0.39%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ADMA is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ALKS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ADMA vs PTGX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while PTGX trades at $136.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas PTGX's P/E ratio is -75.20. In terms of profitability, ADMA's ROE is +0.39%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ADMA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ADMA vs IMGN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ADMA's ROE is +0.39%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ADMA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ADMA vs TGTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while TGTX trades at $56.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas TGTX's P/E ratio is 19.26. In terms of profitability, ADMA's ROE is +0.39%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ADMA is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ADMA vs BPMC Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ADMA's ROE is +0.39%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ADMA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ADMA vs APGE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas APGE's P/E ratio is -31.01. In terms of profitability, ADMA's ROE is +0.39%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ADMA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ADMA vs CERE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CERE's P/E ratio is -16.47. In terms of profitability, ADMA's ROE is +0.39%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ADMA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ADMA vs IMVT Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while IMVT trades at $39.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas IMVT's P/E ratio is -14.76. In terms of profitability, ADMA's ROE is +0.39%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ADMA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ADMA vs PCVX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while PCVX trades at $54.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas PCVX's P/E ratio is -7.94. In terms of profitability, ADMA's ROE is +0.39%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ADMA is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ADMA vs IBRX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while IBRX trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas IBRX's P/E ratio is -8.35. In terms of profitability, ADMA's ROE is +0.39%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ADMA is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
ADMA vs MTSR Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ADMA's ROE is +0.39%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ADMA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ADMA vs RYTM Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while RYTM trades at $102.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas RYTM's P/E ratio is -32.62. In terms of profitability, ADMA's ROE is +0.39%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ADMA is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check RYTM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ADMA vs PRAX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while PRAX trades at $325.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas PRAX's P/E ratio is -24.33. In terms of profitability, ADMA's ROE is +0.39%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ADMA is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check PRAX's competition here
Merus N.V. (NASDAQ: MRUS)
ADMA vs MRUS Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ADMA's ROE is +0.39%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ADMA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check MRUS's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ADMA vs COGT Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while COGT trades at $39.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas COGT's P/E ratio is -18.84. In terms of profitability, ADMA's ROE is +0.39%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ADMA is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check COGT's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ADMA vs ACLX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ADMA's ROE is +0.39%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ADMA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ACLX's competition here
Erasca, Inc. (NASDAQ: ERAS)
ADMA vs ERAS Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ERAS trades at $19.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ERAS's P/E ratio is -20.55. In terms of profitability, ADMA's ROE is +0.39%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ADMA is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check ERAS's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ADMA vs RETA Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas RETA's P/E ratio is -66.29. In terms of profitability, ADMA's ROE is +0.39%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ADMA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check RETA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ADMA vs PTCT Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, PTCT has a market cap of 6.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while PTCT trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas PTCT's P/E ratio is -32.97. In terms of profitability, ADMA's ROE is +0.39%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ADMA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ADMA vs CNTA Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ADMA's ROE is +0.39%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ADMA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CNTA's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ADMA vs SYRE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while SYRE trades at $102.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas SYRE's P/E ratio is -49.10. In terms of profitability, ADMA's ROE is +0.39%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ADMA is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check SYRE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ADMA vs BLTE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while BLTE trades at $153.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas BLTE's P/E ratio is -82.01. In terms of profitability, ADMA's ROE is +0.39%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ADMA is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
ADMA vs CGON Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CGON trades at $69.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CGON's P/E ratio is -29.75. In terms of profitability, ADMA's ROE is +0.39%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ADMA is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CGON's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ADMA vs LGND Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while LGND trades at $300.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas LGND's P/E ratio is 36.03. In terms of profitability, ADMA's ROE is +0.39%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ADMA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ADMA vs SRRK Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while SRRK trades at $47.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas SRRK's P/E ratio is -13.28. In terms of profitability, ADMA's ROE is +0.39%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ADMA is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check SRRK's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ADMA vs MIRM Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, MIRM has a market cap of 5.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while MIRM trades at $113.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas MIRM's P/E ratio is -8.30. In terms of profitability, ADMA's ROE is +0.39%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ADMA is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check MIRM's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ADMA vs CDTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ADMA's ROE is +0.39%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ADMA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ADMA vs ABCM Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ADMA's ROE is +0.39%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ADMA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ADMA vs ISEE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ADMA's ROE is +0.39%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ADMA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ADMA vs TVTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while TVTX trades at $57.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas TVTX's P/E ratio is -260.73. In terms of profitability, ADMA's ROE is +0.39%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ADMA is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ADMA vs APLS Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas APLS's P/E ratio is 38.35. In terms of profitability, ADMA's ROE is +0.39%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ADMA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check APLS's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ADMA vs XENE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, XENE has a market cap of 5.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while XENE trades at $65.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas XENE's P/E ratio is -13.92. In terms of profitability, ADMA's ROE is +0.39%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ADMA is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check XENE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ADMA vs TERN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas TERN's P/E ratio is -51.41. In terms of profitability, ADMA's ROE is +0.39%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ADMA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ADMA vs DFTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while DFTX trades at $43.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas DFTX's P/E ratio is N/A. In terms of profitability, ADMA's ROE is +0.39%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ADMA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
ADMA vs MANE Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while MANE trades at $109.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas MANE's P/E ratio is -34.92. In terms of profitability, ADMA's ROE is +0.39%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ADMA is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ADMA vs FOLD Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ADMA's ROE is +0.39%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ADMA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ADMA vs AKRO Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ADMA's ROE is +0.39%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ADMA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check AKRO's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ADMA vs CRSP Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CRSP trades at $46.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CRSP's P/E ratio is -9.11. In terms of profitability, ADMA's ROE is +0.39%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ADMA is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check CRSP's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ADMA vs ALPN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ADMA's ROE is +0.39%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ADMA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ADMA vs EWTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while EWTX trades at $40.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas EWTX's P/E ratio is -24.60. In terms of profitability, ADMA's ROE is +0.39%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ADMA is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check EWTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ADMA vs CAI Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CAI trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CAI's P/E ratio is -85.37. In terms of profitability, ADMA's ROE is +0.39%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ADMA is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ADMA vs DNTH Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while DNTH trades at $103.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas DNTH's P/E ratio is -25.15. In terms of profitability, ADMA's ROE is +0.39%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ADMA is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ADMA vs ACAD Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ACAD trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ACAD's P/E ratio is 12.18. In terms of profitability, ADMA's ROE is +0.39%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ADMA is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check ACAD's competition here
Opthea Limited (NASDAQ: OPT)
ADMA vs OPT Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas OPT's P/E ratio is -1.52. In terms of profitability, ADMA's ROE is +0.39%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ADMA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ADMA vs MRTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ADMA's ROE is +0.39%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ADMA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ADMA vs LEGN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while LEGN trades at $22.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas LEGN's P/E ratio is -32.68. In terms of profitability, ADMA's ROE is +0.39%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ADMA is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check LEGN's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ADMA vs DYN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, DYN has a market cap of 4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while DYN trades at $24.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas DYN's P/E ratio is -7.59. In terms of profitability, ADMA's ROE is +0.39%, compared to DYN's ROE of -0.58%. Regarding short-term risk, ADMA is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check DYN's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ADMA vs VKTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while VKTX trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas VKTX's P/E ratio is -8.40. In terms of profitability, ADMA's ROE is +0.39%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ADMA is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
ADMA vs CELC Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CELC has a market cap of 4B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CELC trades at $82.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CELC's P/E ratio is -21.18. In terms of profitability, ADMA's ROE is +0.39%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ADMA is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ADMA vs CPRX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ADMA's ROE is +0.39%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ADMA is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ADMA vs ELVN Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ELVN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ELVN's P/E ratio is -31.71. In terms of profitability, ADMA's ROE is +0.39%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ADMA is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ADMA vs RYZB Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ADMA's ROE is +0.39%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ADMA is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ADMA vs CBAY Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ADMA's ROE is +0.39%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ADMA is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check CBAY's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ADMA vs DNLI Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while DNLI trades at $23.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas DNLI's P/E ratio is -8.02. In terms of profitability, ADMA's ROE is +0.39%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ADMA is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check DNLI's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
ADMA vs NAMSW Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas NAMSW's P/E ratio is -10.50. In terms of profitability, ADMA's ROE is +0.39%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, ADMA is less volatile compared to NAMSW. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ADMA vs ADPT Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while ADPT trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas ADPT's P/E ratio is -41.24. In terms of profitability, ADMA's ROE is +0.39%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, ADMA is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check ADPT's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
ADMA vs SWTX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ADMA's ROE is +0.39%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ADMA is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
ADMA vs NAMS Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while NAMS trades at $29.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas NAMS's P/E ratio is -18.64. In terms of profitability, ADMA's ROE is +0.39%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ADMA is less volatile compared to NAMS. This indicates lower risk in terms of short-term price fluctuations for ADMA.Check NAMS's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ADMA vs TLX Comparison July 2026
ADMA Biologics, Inc. (NASDAQ: ADMA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMA stands at 1.9B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, ADMA is priced at $8.27 on the NASDAQ, while TLX trades at $10.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMA currently has a P/E ratio of 11.81, whereas TLX's P/E ratio is -555.43. In terms of profitability, ADMA's ROE is +0.39%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ADMA is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ADMA.Check TLX's competition here